Featured Research

from universities, journals, and other organizations

Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration

Date:
June 15, 2011
Source:
JAMA and Archives Journals
Summary:
A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white individuals, according to a new study.

A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white individuals, according to a report in the June issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

"Before ranibizumab became available in 2006, neovascular age-related macular degeneration (AMD) was reported to be the leading cause of blindness in individuals 50 years and older in the United States and throughout many parts of the world," the authors write as background information in the article.

To estimate the number of individuals in the United States who may benefit from treatment with ranibizumab to treat neovascular AMD (occurs when new blood vessels form in the retinal tissue, that can break easily, causing bleeding and damage to surrounding tissue) and prevent AMD-related blindness, Neil M. Bressler, M.D., of Wilmer Eye Institute, The Johns Hopkins University, Baltimore, and colleagues designed a modeling study using outcomes from three previous phase 3 ranibizumab trials.

Using statistics from the Beaver Dam Eye Study and data from the 2008 U.S. Census Bureau, the model predicted that 151,340 non-Hispanic white individuals in 2008 would develop neovascular AMD. Using data from the Age-Related Eye Disease Study (a phase 3 ranibizumab trial), the authors estimated that one-third of these cases (51,000 individuals) would already have preexisting choroidal neovascularization (new blood vessels form in the choroid, a thin vascular layer that supplies blood to the retina) in the opposite eye, making those patients ineligible for the model used in this study. Of the 151,340 individuals, the authors estimated that ranibizumab would be accessible to 103,582 individuals, making them eligible for inclusion in the study's modeling criteria.

Based on the model designed for the study, if no treatment were given to the 103,582 cases for which monthly ranibizumab was indicated and accessible, 16,268 (16 percent) would progress to legal blindness in two years. The authors estimated that monthly ranibizumab usage would reduce the incidence of legal blindness in two years by 72 percent, to 4,484 individuals. Additionally, based on the model designed for the study, if no treatment were applied to the 103,582 cases for which monthly ranibizumab is indicated and accessible, 34,702 (34 percent) would progress in two years to visual impairment (worse than 20/40 in the better-seeing eye, a level that precludes an unrestricted driver's license in most states). The authors estimated that monthly ranibizumab usage would reduce the incidence of visual impairment in two years by 37 percent, to 21,919 individuals.

Based on results of the model designed for this study, the authors conclude that ranibizumab would have an effect on reducing the occurrence of visual blindness in individuals with AMD when treatment is administered on a monthly basis when available.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Neil M. Bressler; Quan V. Doan; Rohit Varma; Paul P. Lee; Ivan J. Suner; Chantal Dolan; Mark D. Danese; Elaine Yu; Irwin Tran; Shoshana Colman. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic White Population in the United States With Age-Related Macular Degeneration. Archives of Ophthalmology, 2011; 129 (6): 709-717 DOI: 10.1001/archophthalmol.2011.140

Cite This Page:

JAMA and Archives Journals. "Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration." ScienceDaily. ScienceDaily, 15 June 2011. <www.sciencedaily.com/releases/2011/06/110613162101.htm>.
JAMA and Archives Journals. (2011, June 15). Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/06/110613162101.htm
JAMA and Archives Journals. "Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration." ScienceDaily. www.sciencedaily.com/releases/2011/06/110613162101.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins